Search

Your search keyword '"Lahuerta J.-J."' showing total 114 results
Start Over Author "Lahuerta J.-J." Publication Type Academic Journals
114 results on '"Lahuerta J.-J."'

1. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

Author

Medina-Herrera, A., Vazquez, I., Cuenca, I., Rosa-Rosa, J. M., Ariceta, B., Jimenez, C., Fernandez-Mercado, M., Larrayoz, M. J., Gutierrez, N. C., Fernandez-Guijarro, M., Gonzalez-Calle, V., Rodriguez-Otero, P., Oriol, A., Rosiñol, L., Alegre, A., Escalante, F., De La Rubia, J., Teruel, A. I., De Arriba, F., Hernandez, M. T., Lopez-Jimenez, J., Ocio, E. M., Puig, N., Paiva, B., Lahuerta, J. J., Bladé, J., San Miguel, J. F., Mateos, M. V., Martinez-Lopez, J., Calasanz, M. J., and Garcia-Sanz, R.

Published
2024
Full Text
View/download PDF

2. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Author

Kumar, S K, Dimopoulos, M A, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, E M, Mateos, M V, O'Donnell, E K, Vij, R, Lokhorst, H M, van de Donk, N W C J, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, S Z, Dytfeld, D, Badros, A Z, Moreau, P, Kim, K, Otero, P R, Lee, J H, Shustik, C, Waller, D, Chng, W J, Ozaki, S, Lee, J-J, de la Rubia, J, Eom, H S, Rosinol, L, Lahuerta, J J, Sureda, A, Kim, J S, and Durie, B G M

Published
2017
Full Text
View/download PDF

4. Differentiation stage of myeloma plasma cells: biological and clinical significance

Author

Paiva, B, Puig, N, Cedena, M T, de Jong, B G, Ruiz, Y, Rapado, I, Martinez-Lopez, J, Cordon, L, Alignani, D, Delgado, J A, van Zelm, M C, Van Dongen, J J M, Pascual, M, Agirre, X, Prosper, F, Martín-Subero, J I, Vidriales, M-B, Gutierrez, N C, Hernandez, M T, Oriol, A, Echeveste, M A, Gonzalez, Y, Johnson, S K, Epstein, J, Barlogie, B, Morgan, G J, Orfao, A, Blade, J, Mateos, M V, Lahuerta, J J, and San-Miguel, J F

Published
2017
Full Text
View/download PDF

6. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

Author

Flores-Montero, J, Sanoja-Flores, L, Paiva, B, Puig, N, García-Sánchez, O, Böttcher, S, van der Velden, V HJ, Pérez-Morán, J-J, Vidriales, M-B, García-Sanz, R, Jimenez, C, González, M, Martínez-López, J, Corral-Mateos, A, Grigore, G-E, Fluxá, R, Pontes, R, Caetano, J, Sedek, L, del Cañizo, M-C, Bladé, J, Lahuerta, J-J, Aguilar, C, Bárez, A, García-Mateo, A, Labrador, J, Leoz, P, Aguilera-Sanz, C, San-Miguel, J, Mateos, M-V, Durie, B, van Dongen, J JM, and Orfao, A

Published
2017
Full Text
View/download PDF

7. Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Author

Musto, P., Anderson, K. C., Attal, M., Richardson, P. G., Badros, A., Hou, J., Comenzo, R., Du, J., Durie, B. G. M., San Miguel, J., Einsele, H., Chen, W. M., Garderet, L., Pietrantuono, G., Hillengass, J., Kyle, R. A., Moreau, P., Lahuerta, J. J., Landgren, O., Ludwig, H., Larocca, A., Mahindra, A., Cavo, M., Mazumder, A., McCarthy, P. L., Nouel, A., Rajkumar, S. V., Reiman, A., Serra, E. R., Sezer, O., Terpos, E., Turesson, I., Usmani, S., Weiss, B. M., and Palumbo, A.

Published
2017
Full Text
View/download PDF

8. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

Author

Paíno, T, Paiva, B, Sayagués, J M, Mota, I, Carvalheiro, T, Corchete, L A, Aires-Mejía, I, Pérez, J J, Sanchez, M L, Barcena, P, Ocio, E M, San-Segundo, L, Sarasquete, M E, García-Sanz, R, Vidriales, M-B, Oriol, A, Hernández, M-T, Echeveste, M-A, Paiva, A, Blade, J, Lahuerta, J-J, Orfao, A, Mateos, M-V, Gutiérrez, N C, and San-Miguel, J F

Published
2015
Full Text
View/download PDF

9. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

Author

Ocio, E M, Richardson, P G, Rajkumar, S V, Palumbo, A, Mateos, M V, Orlowski, R, Kumar, S, Usmani, S, Roodman, D, Niesvizky, R, Einsele, H, Anderson, K C, Dimopoulos, M A, Avet-Loiseau, H, Mellqvist, U-H, Turesson, I, Merlini, G, Schots, R, McCarthy, P, Bergsagel, L, Chim, C S, Lahuerta, J J, Shah, J, Reiman, A, Mikhael, J, Zweegman, S, Lonial, S, Comenzo, R, Chng, W J, Moreau, P, Sonneveld, P, Ludwig, H, Durie, B G M, and Miguel, J F S

Published
2014
Full Text
View/download PDF

10. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Author

Puig, N, Sarasquete, M E, Balanzategui, A, Martínez, J, Paiva, B, García, H, Fumero, S, Jiménez, C, Alcoceba, M, Chillón, M C, Sebastián, E, Marín, L, Montalbán, M A, Mateos, M V, Oriol, A, Palomera, L, de la Rubia, J, Vidriales, M B, Bladé, J, Lahuerta, J J, González, M, Miguel, J F S, and García-Sanz, R

Published
2014
Full Text
View/download PDF

11. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

Author

Paiva, B, Vídriales, M-B, Rosiñol, L, Martínez-López, J, Mateos, M-V, Ocio, E M, Montalbán, M-Á, Cordón, L, Gutiérrez, N C, Corchete, L, Oriol, A, Terol, M-J, Echeveste, M-A, De Paz, R, De Arriba, F, Palomera, L, de la Rubia, J, Díaz-Mediavilla, J, Granell, M, Gorosquieta, A, Alegre, A, Orfao, A, Lahuerta, J-J, Bladé, J, and Miguel, J F San

Published
2013
Full Text
View/download PDF

12. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Author

Fernández de Larrea, C, Kyle, R A, Durie, B G M, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Bladé, J, Orlowski, R Z, and Shah, J J

Published
2013
Full Text
View/download PDF

13. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

Author

Paiva, B, Gutiérrez, N-C, Chen, X, Vídriales, M-B, Montalbán, M-Á, Rosiñol, L, Oriol, A, Martínez-López, J, Mateos, M-V, López-Corral, L, Díaz-Rodríguez, E, Pérez, J-J, Fernández-Redondo, E, de Arriba, F, Palomera, L, Bengoechea, E, Terol, M-J, de Paz, R, Martin, A, Hernández, J, Orfao, A, Lahuerta, J-J, Bladé, J, Pandiella, A, and Miguel, J-F San

Published
2012
Full Text
View/download PDF

14. Management of treatment-emergent peripheral neuropathy in multiple myeloma

Author

Richardson, P G, Delforge, M, Beksac, M, Wen, P, Jongen, J L, Sezer, O, Terpos, E, Munshi, N, Palumbo, A, Rajkumar, S V, Harousseau, J L, Moreau, P, Avet-Loiseau, H, Lee, J H, Cavo, M, Merlini, G, Voorhees, P, Chng, W J, Mazumder, A, Usmani, S, Einsele, H, Comenzo, R, Orlowski, R, Vesole, D, Lahuerta, J J, Niesvizky, R, Siegel, D, Mateos, M-V, Dimopoulos, M, Lonial, S, Jagannath, S, Bladé, J, Miguel, J San, Morgan, G, Anderson, K C, Durie, B G M, and Sonneveld, P

Published
2012
Full Text
View/download PDF

15. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Author

Kumar, S K, Lee, J H, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, LeLeu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, S V, and Durie, B G M

Published
2012
Full Text
View/download PDF

16. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

Author

Paiva, B, Pérez-Andrés, M, Vídriales, M-B, Almeida, J, de las Heras, N, Mateos, M-V, López-Corral, L, Gutiérrez, N C, Blanco, J, Oriol, A, Hernández, M T, de Arriba, F, de Coca, A G, Terol, M-J, de la Rubia, J, González, Y, Martín, A, Sureda, A, Schmidt-Hieber, M, Schmitz, A, Johnsen, H E, Lahuerta, J-J, Bladé, J, San-Miguel, J F, and Orfao, A

Published
2011
Full Text
View/download PDF

17. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

Author

Gutiérrez, N C, Castellanos, M V, Martín, M L, Mateos, M V, Hernández, J M, Fernández, M, Carrera, D, Rosiñol, L, Ribera, J M, Ojanguren, J M, Palomera, L, Gardella, S, Escoda, L, Hernández-Boluda, J C, Bello, J L, de la Rubia, J, Lahuerta, J J, and San Miguel, J F

Published
2007
Full Text
View/download PDF

18. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Author

de Larrea, Fernandez C, Kyle, R A, Durie, B GM, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Blade, J, Orlowski, R Z, and Shah, J J

Published
2013
Full Text
View/download PDF

21. Results of pre- and post-autologous stem cell transplantation with three induction regimens in multiple myeloma: superiority of VTD (bortezomib /thalidomide /dexamethasone) over TD and VBMCP/VBAD plus bortezomib (VBMCP/VBAD/V): 0271

Author

Rosiñol, L., Cibeira, M. T., Mateos, M. V., Gutierrez, N., Martínez, J., Oriol, A., Teruel, A. I., Hernández, D., García-Laraña, J., de la Rubia, J., Sureda, A., Besalduch, J., Palomera, L., González, Y., Etxebeste, M. A., Díaz-Mediavilla, J., Hernández, M. T., de Arriba, F., Alegre, A., Lahuerta, J. J., Miguel, San J., and Bladé, J.

Published
2011

22. High-dose therapy/autologous stem cell transplantation increases complete remission rate in multiple myeloma irrespective of the induction regimen used: TD (Thalidomide/dexamethasone), VTD (bortezomib/thalidomide/dexamethasone) or VBMCP/VBAD plus bortezom: O162

Author

Rosiñol, L., Cibeira, M. T., Martínez, J., Mateos, M. V., Terol, M. J., de la Rubia, J., Palomera, L., de Arriba, F., Oriol, A., Alegre, A., Besalduch, J., de Paz, R., García-Laraña, J., Díaz-Mediavilla, J., Sureda, A., Lahuerta, J. J., San Miguel, J., and Bladé, J.

Published
2009

27. Effectiveness of Lenalidomide in Patients with Relapsed or Progressive Multiple Myeloma: A114

Author

Amor, A A, Casanova, M, Fuertes, M, Guzmán, J L, Bueno, B A, Giraldo, P, Cánovas, A, Ibáñez, A, Castillo, I, Blanes, M, Ríos, E, Rodríguez, J N, Palomera, L, Hernández, M T, Oriol, A, Sancho, E, Menchaca, C, Vercher, J, González, A P, Arilla, M J, Ramírez, G, Pérez, R, Asensio, A, de la Serna, J, Osorio, S, Aguilar, C, Ansó, V, Calvo, J M, López, L, López, A, Olalla, J I, Hernández, J M, Petit, J, Ríos, P, Villalón, L, García, I, García, A, Larregla, S, García-Escribano, F L, and Lahuerta, J J

Published
2009

31. Tandem autologous transplant versus reduced-intensity conditioned allogeneic transplant in chemosensitive patients with multiple myeloma not achieving complete remission or near-CR with a first autologous transplant. Final results from a PHETEMA study

Author

Rosiñol, L., Lahuerta, J. J., Sureda, A., de la Rubia, J., García-Laraña, J., Hernández-García, M., Hernández-Ruíz, B., Pérez-Simón, J. A., Bello, J. L., Carrera, D., Peñarrubia, M. J., Abella, E., León, A., Poderós, C., García-Ruíz, J. C., Besalduch, J., Martínez-Martínez, R., Fernández-Pérez, I., Ribas, P., San Miguel, J., and Bladé, J.

Published
2008

33. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkinʼs lymphoma autografted after a first relapse

Author

Sureda, A., Constans, M., Iriondo, A., Arranz, R., Caballero, M. D., Vidal, M. J., Petit, J., López, A., Lahuerta, J. J., Carreras, E., García-Conde, J., García-Laraña, J., Cabrera, R., Jarque, I., Carrera, D., García-Ruiz, J. C., Pascual, M. J., Rifón, J., Moraleda, J. M., Pérez-Equiza, K., Albó, C., Díaz-Mediavilla, J., Torres, A., Torres, P., Besalduch, J., Marín, J., Mateos, M. V., Fernández-Rañada, J. M., Sierra, J., and Conde, E.

Published
2005

34. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkinʼs lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience

Author

Rodriguez, J., Caballero, M. D., Gutierrez, A., Solano, C., Arranz, R., Lahuerta, J. J., Sierra, J., Gandarillas, M., Perez-Simon, J. A., Zuazu, J., Lopez-Guillermo, A., Sureda, A., Carreras, E., Garcia-Laraña, J., Marin, J., Garcia, J. C., Fernandez de Sevilla, A., Rifon, J., Varela, R., Jarque, I., Albo, C., Leon, A., Miguel, J. San, and Conde, E.

Published
2004

38. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group

Author

Caballero, M. D., Pérez-Simón, J. A., Iriondo, A., Lahuerta, J. J., Sierra, J., Marín, J., Gandarillas, M., Arranz, R., Zuazu, J., Rubio, V., de Sevilla, A. Fernández, Carreras, E., García-Conde, J., García-Laraña, J., Grande, C., Sureda, A., Vidal, M. J., Rifón, J., Pérez-Equiza, C., Varela, R., Moraleda, J. M., Ruíz, J. C. García, Albó, C., Cabrera, R., Miguel, J. F. San, and Conde, E.

Published
2003

39. Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

Author

Paiva, B, Vídriales, M-B, Rosiñol, L, Martínez-López, J, Mateos, M-V, Ocio, E M, Montalbán, M-Á, Cordón, L, Gutiérrez, N C, Corchete, L, Oriol, A, Terol, M-J, Echeveste, M-A, De Paz, R, De Arriba, F, Palomera, L, de la Rubia, J, Díaz-Mediavilla, J, Granell, M, Gorosquieta, A, Alegre, A, Orfao, A, Lahuerta, J-J, Bladé, J, and San Miguel, J F

Published
2013
Full Text
View/download PDF

40. Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Author

Kumar, S K, Lee, J H, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, LeLeu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladeé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, and Rajkumar, S V

Published
2012
Full Text
View/download PDF

41. Papain‐treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti‐CD38‐based therapies.

Author

Carreño‐Tarragona, G., Cedena, T., Montejano, L., Alonso, R., Miras, F., Valeri, A., Rivero, A., Lahuerta, J. J., and Martinez‐Lopez, J.

Subjects
MULTIPLE myeloma, BLOOD banks, MONOCLONAL antibodies, BLOOD transfusion, COOMBS' test, RED blood cell transfusion
Abstract

SUMMARY: Objectives: To report our 2 years of experience navigating the interference of anti‐CD38 monoclonal antibodies (MAs) in 33 patients and describe papain‐treated panels as a complementary method to dithiothreitol (DTT). Background: Novel anti‐CD38 MAs are now approved or undergoing clinical trials to evaluate their activity in patients with multiple myeloma. A concern with the use of these drugs is that they interfere with blood bank tests in a group of patients who often require blood transfusions. Methods: Clinical data and whole blood samples were collected from patients receiving daratumumab or isatuximab. Routine blood bank serological tests were performed. Results: A total of 9·1% of patients presented with alloantibodies prior to treatment. All patients exhibited nonspecific reactivity in indirect antiglobulin tests, and 26% had positive direct antiglobulin tests after beginning treatment. This interference disappeared in all patients after discontinuing treatment. Papain panels avoided this reactivity and allowed us to identify alloantibodies. Phenotyped blood units were transfused, and no patient suffered any transfusion‐related complications. Conclusion: Anti‐CD38 MAs produce nonspecific interference in blood bank tests. This interference can be overcome by various methods, including DTT or papain treatment as proposed here. These methods have limitations that can be resolved using phenotyped blood units. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

42. Autologous stem cell transplantation for clinically aggressive non-Hodgkin’s lymphoma: the role of preparative regimens.

Author

Salar, A, Sierra, J, Gandarillas, M, Caballero, M D, Marín, J, Lahuerta, J J, García-Conde, J, Arranz, R, León, A, Zuazu, J, García-Laraña, J, López-Guillermo, A, Sanz, M A, Grañena, A, García, J C, and Conde, E

Subjects
AUTOTRANSPLANTATION, STEM cell transplantation, HODGKIN'S disease
Abstract

We investigated the impact of the most commonly used preparative regimens on the outcome of 395 patients with diffuse large cell lymphoma (DLCL), consecutively reported to the registry of the Spanish GEL/TAMO. Among them, 139 (35%) were autografted in 1st CR, 86 (22%) in 2nd/3rd CR, 124 (31%) had chemosensitive disease and 46 (12%) had chemoresistant disease. Conditioning consisted of chemotherapy-only in 348 patients (BEAM, 164; BEAC, 145; and CBV, 39) and radiochemotherapy with CY and TBI in 47. Median times to granulocyte, platelet recovery and to discharge were significantly shorter in the chemotherapy-only group. Early transplant-related mortality was significantly higher when using CY-TBI. After a median follow-up of 28 months, overall survival (OS) at 8 years of patients conditioned with BEAM or BEAC (58% (95% CI 50–66%)) was more favorable than with CBV (40% (95% CI 24–56%)), and significantly better than with CY-TBI (31% (95% CI 18–44%)). Multivariate analysis revealed that patients conditioned with chemotherapy-only regimens had improved OS, disease-free (DFS) and relapse-free survival (RFS) when compared to those conditioned with CY-TBI. Status at transplant was also a powerful prognostic indicator. We conclude that preparative regimens consisting of chemotherapy-only seem more efficacious than CY-TBI as conditioning for DLCL, because of faster engraftment and greater anti-lymphoma effect, as indicated by improved OS, DFS and RFS. Bone Marrow Transplantation (2001) 27, 405–412. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

43. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

Author

San Miguel, J F, Lahuerta, J J, García-Sanz, R, Alegre, A, Bladé, J, Martinez, R, García-Laraña, J, De la Rubia, J, Sureda, A, Vidal, M J, Escudero, A, Pérez-Esquiza, E, Conde, E, García-Ruiz, J C, Cabrera, R, Caballero, D, Moraleda, J M, Leon, A, and Besalduch, J

Subjects
*MULTIPLE myeloma, *MYELOID leukemia
Abstract

Introduction: Renal function is one of the most important prognostic factors in multiple myeloma (MM). Patients with renal failure are generally excluded from high dose therapy even though they display a poor prognosis with conventional chemotherapy schemes. The aim of this study was to analyze the outcome of MM patients with renal insufficiency undergoing autologous stem cell transplantation (ASCT), including the evaluation of the quality of PB stem cell collections, kinetics of engraftment, transplant-related mortality, response to high dose chemotherapy and survival. Materials and methods: From a total of 566 valuable patients included in the MM Spanish ASCT registry, three groups of patients were defined: group BA, patients with abnormal renal function at diagnosis but normal at transplant (73 cases); group BB, patients with abnormal function both at diagnosis and at transplant (14 cases); and group AA (control group, 479 cases), patients who constantly had normal renal function. Results and conclusion: Patients from groups BA and BB presented with a significantly higher number of adverse prognostic factors, reflecting that we were dealing with high tumor MM cases, as compared with patients from group AA. The number of mononuclear cells, CD34+ cells and CFU-GM cells collected in patients with non-reversible renal insufficiency was similar to those harvested in MM patients with normal renal function. Moreover, neutrophil and platelet engraftments were identical in patients with and without renal failure (days +11 and +12, respectively). By contrast, transplant-related mortality (TRM) was significantly higher in group BB patients (29%) than in groups BA (4.1%) and AA (3.3%). In multivariate analysis only three variables showed independent influence on TRM: poor performance status (ECOG 3), hemoglobin <9.5 g/dl and serum creatinine &ges;5 mg/dl. The response to high dose therapy was independent of renal function. Interestingly, 43% of patients from group BB... [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

44. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry.

Author

Alegre, A., Díaz-Mediavilla, J., San-Miguel, J., Martínez, R., García Laraña, J., Sureda, A., Lahuerta, J. J., Morales, D., Bladé, J., Caballero, D., De la Rubia, J., Escudero, A., Díez-Martín, J. L., Hernández-Navarro, F., Rifón, J., Odriozola, J., Brunet, S., De la Serna, J., Besalduch, J., and Vidal, M. J.

Subjects
STEM cell transplantation, MULTIPLE myeloma
Abstract

Between January 1989 and November 1995, 259 patients with multiple myeloma (MM), 22 stage I, 57 stage II and 180 stage III at diagnosis were treated with myeloablative high-dose therapy followed by autologous peripheral blood stem cell (PBSC) transplantation. The median time from diagnosis to transplantation was 17 months (6–112). At the time of transplant, 56 patients were in CR, 153 in PR, 25 were nonresponders and 25 had progressive disease. Mobilization of stem cells was performed with G-CSF alone in 141 cases, chemotherapy plus G-CSF in 65, chemotherapy plus GM-CSF in 36 and chemotherapy alone in 17 patients. The conditioning regimen consisted of high-dose melphalan alone in 96 patients, melphalan plus TBI in 73, busulfan plus melphalan in 56, busulfan plus cyclophosphamide in 27 and cyclophosphamide plus TBI in seven. The median durations of neutropenia (>0.5 × 109/l) and thrombocytopenia (>20 × 109/l) were 12 (5–118) and 13 days (5–360), respectively. Transplant-related mortality occurred in 11 patients (4%). Once a stable graft was achieved, 114 patients (44%) received maintenance treatment with recombinant alpha interferon (IFN-α). Among the 248 patients evaluable for response 125 (51%) had a CR and 100 had a PR (40%). The median duration of progression-free survival (PFS) and overall survival (OS) after transplantation was 23 and 35 months, respectively. Univariate analysis showed that response status pretransplant, only one line of primary induction treatment and IFN-αmaintenance treatment post-transplant significantly influenced OS. Female sex, pretransplant responsive disease, and treatment with IFN-α post-transplant were the factors significantly influencing PFS. The conditioning regimen and method of stem cell mobilization had no significant impact on OS and PFS. On multivariate analysis the only independent factors associated with a longer survival were the number of... [ABSTRACT FROM AUTHOR]

Published
1998

45. Autologous stem cell transplantation for poor prognosis Hodgkin’s disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group.

Author

Sureda, A., Mataix, R., Hernández-Navarro, F., Jarque, I., Lahuerta, J. J., Tomás, J. F., Brunet, S., Caballero, D., Conde, E., León, A., Fernández, M. N., López, A., Maldonado, J., Bengoechea, E., Callís, M., Carrera, D., García-Conde, J., García-Laraña, J., Moraleda, J. M., and Morey, M.

Subjects
HODGKIN'S disease, CELL transplantation, STEM cells, DRUG therapy
Abstract

Although more than 50% of Hodgkin’s disease patients are cured with conventional chemotherapy, many will relapse and eventually die from their disease. Many efforts have been made to identify poor prognostic factors that could be useful in selecting high-risk patients in 1st CR who may benefit from high-dose chemo/radiotherapy. However, the role of early transplantation in 1st CR remains unclear. We have retrospectively analyzed the results obtained with this procedure in 22 hospitals belonging to the Spanish GEL/TAMO cooperative group. Twenty-seven patients, of whom 19 were males, underwent autologous transplantation for Hodgkin’s disease in 1st CR between January 1987 and January 1996. Remission had been achieved after one (n = 22) or two (n = 5) lines of treatment. Twenty-four patients had advanced stage disease, 12 patients bulky mediastinal disease, nine bone marrow involvement and 18 had extranodal disease. Peripheral blood was used as the source of hematopoietic stem cells in 15 patients, BM in nine, and both in three. All but three patients received chemotherapy-based conditioning regimens (16 CBV, four BEAM and four BEAC), while three were conditioned with CY and TBI. There were no transplant-related deaths. Median (range) times to recover >0.5 × 109/l neutrophils and >50 × 109/l platelets were 14 (8–56) days and 16 (8–240) days, respectively. With a median follow-up of 30 (8–66) months, 21 patients are alive and in continuous CR. Four patients who relapsed after transplant at 8, 17.5, 22 and 26 months achieved a second CR with conventional chemotherapy; one patient relapsed 92 months post-transplant and died 5 months afterwards. Another patient died 30.5 months post-transplant from a secondary malignancy. In conclusion, high-dose therapy in poor prognosis Hodgkin’s disease in 1st CR was well tolerated with no transplant-related mortalities. Although the follow-up of this series... [ABSTRACT FROM AUTHOR]

Published
1997
Full Text
View/download PDF

46. Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Author

Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, and Palumbo A

Published
2018
Full Text
View/download PDF

47. Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Author

Arana P, Paiva B, Cedena MT, Puig N, Cordon L, Vidriales MB, Gutierrez NC, Chiodi F, Burgos L, Anglada LL, Martinez-Lopez J, Hernandez MT, Teruel AI, Gironella M, Echeveste MA, Rosiñol L, Martinez R, Oriol A, De la Rubia J, Orfao A, Blade J, Lahuerta JJ, Mateos MV, and San Miguel JF

Subjects
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local pathology, Neoplasm, Residual metabolism, Neoplasm, Residual pathology, Prognosis, Antigens, CD metabolism, Multiple Myeloma metabolism, Multiple Myeloma pathology
Abstract

Persistence of minimal residual disease (MRD) after treatment for myeloma predicts inferior outcomes, but within MRD-positive patients there is great heterogeneity with both early and very late relapses. Among different MRD techniques, flow cytometry provides additional information about antigen expression on tumor cells, which could potentially contribute to stratify MRD-positive patients. We investigated the prognostic value of those antigens required to monitor MRD in 1265 newly diagnosed patients enrolled in the GEM2000, GEM2005MENOS65, GEM2005MAS65 and GEM2010MAS65 protocols. Overall, CD19 pos , CD27 neg , CD38 lo , CD45 pos , CD81 pos , CD117 neg and CD138 lo expression predicted inferior outcomes. Through principal component analysis, we found that simultaneous CD38 low CD81 pos CD117 neg expression emerged as the most powerful combination with independent prognostic value for progression-free survival (HR:1.69; P=0.002). This unique phenotypic profile retained prognostic value among MRD-positive patients. We then used next-generation flow to determine antigen stability throughout the course of the disease, and found that the expression of antigens required to monitor MRD is mostly stable from diagnosis to MRD stages, except for CD81 whose expression progressively increased from baseline to chemoresistant tumor cells (14 vs 28%). Altogether, we showed that the phenotypic profile of tumor cells provides additional prognostic information, and could be used to further predict risk of relapse among MRD-positive patients.

Published
2018
Full Text
View/download PDF

48. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.

Author

Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Marin C, Cedena MT, Paiva B, Puig N, Mateos MV, Ayala R, Hernández MT, Jimenez C, Rosiñol L, Martínez R, Teruel AI, Gutiérrez N, Martin-Ramos ML, Oriol A, Bargay J, Bladé J, San-Miguel J, Garcia-Sanz R, and Lahuerta JJ

Subjects
Aged, Female, Humans, Male, Monitoring, Physiologic, Multiple Myeloma genetics, Multiple Myeloma pathology, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, High-Throughput Nucleotide Sequencing methods, Multiple Myeloma drug therapy, Neoplasm, Residual physiopathology
Published
2017
Full Text
View/download PDF

50. [Effect on plasma fibrinogen of hypercholesterolaemia treatment with pravastatin].

Author

Murciano Revert J, Martínez-Lahuerta JJ, Aleixandre Porcar L, and Debón Belda M

Subjects
Female, Follow-Up Studies, Humans, Hypercholesterolemia blood, Male, Middle Aged, Prospective Studies, Anticholesteremic Agents therapeutic use, Fibrinogen drug effects, Hypercholesterolemia drug therapy, Pravastatin therapeutic use
Abstract

Objective: To determine whether hypercholesterolaemia treatment with pravastatin causes modifications in plasma fibrinogen., Design: Descriptive, prospective pharmacological intervention study, with two transversal cuts, one at the start and one after 6 months pravastatin treatment., Setting: Health area located in the suburbs of Valencia., Patients: Hypercholesterolaemia cases diagnosed de novo and treated with pravastatin for 6 months. Sample size was calculated for paired data with an alpha error of 0.05 and a beta error of 20%. The fibrinogen difference thought relevant was set at 40 mg/dl. Variability was deduced from a mini-sample of 15 cases, obtaining a total of 57 patients. Sex, age, height, weight, BMI, count, formula, globular sedimentation rate (GSR), glucaemia, total, HDL and LDL cholesterol, and triglycerides were recorded., Measurements and Main Results: Mean age was 55.9, height 161.9 cm and initial weight 73.9 kg (mean BMI 28.1 kg/m(2)). After six months pravastatin treatment (10/20 mg/day) we found no significant differences in glucaemia, GSR or leukocytes. There were differences in weight, that fell by 1.5 kg (0.6 kg/m(2)), systolic pressure (4.3 mmHg) and diastolic pressure (2.7 mmHg) on average. We found the following differences for lipids: 42.3 mg/dl (15.2%) drop in mean total cholesterol, 27 mg/dl (14.5%) in LDL cholesterol, and 36.2 mg/dl (21.9%) in triglycerides. We found a mean increase in HDL cholesterol of 4.4 mg/dl. There was a mean drop of 43.7 mg/dl (11.9%) in fibrinogen., Conclusions: We found an 11.9% drop of plasma fibrinogen in patients with hypercholesterolaemia treated with pravastatin.

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results